Navigation Links
SuviCa Inc. of Boulder to commercialize CU-Boulder cancer screening technology
Date:9/19/2011

SuviCa Inc. of Boulder and the University of Colorado recently completed an exclusive license agreement for a CU drug screening technology to identify novel therapies for cancer.

The patented drug discovery tool, developed by CU-Boulder Associate Professor Tin Tin Su of the molecular, cellular and developmental biology department, uses a genetically modified Drosophila fruit fly model to screen for compounds effective against various types of cancer, either alone or in combination with existing therapies.

The screening technique will be used to identify new clinical candidates using a methodology that is both time efficient and cost-effective. Because it uses a whole-animal screening model, the technique can more easily eliminate drug candidates with undesired toxicity.

"SuviCa looks forward to advancing Dr. Su's technology in order to find better ways to treat cancer patients and to build a world-class business in the Front Range region," said Judy Hemberger, SuviCa's chairman and CEO.

"We are excited about the commercial possibilities for the drug screening technology developed by Dr. Su, which has already been used at CU to identify promising therapeutic candidates," said Tom Smerdon, director of licensing and new business development at the CU Technology Transfer Office, or TTO.

SuviCa recently received funding from Colorado's Bioscience Discovery Evaluation Grant Program, an initiative launched in 2007 by the state of Colorado's Office of Economic Development and International Trade to provide early-stage, matching seed grants to enable the development and commercial validation of promising technologies that are licensed from Colorado research institutions.

SuviCa also has received a grant from the Internal Revenue Service through the Qualifying Therapeutic Discovery Project Program aimed at small businesses. Current and future efforts will focus on identifying and optimizing additional lead compounds to enter into formal clinical testing.

SuviCa Inc. is an early-stage cancer drug discovery and development company co-founded by Su, who now serves as its chief science officer. Judith Hemberger, a former co-founder and COO of Boulder-based Pharmion, has joined the senior management team as chairman and CEO.

Working in close collaboration with scientists at CU-Boulder, the University of Colorado Anschutz Medical Campus and Colorado State University, SuviCa is pursuing a promising discovery process based on several small molecules initially identified using its proprietary screening technology and targeted to a distinct cellular process. SuviCa researchers hope to discover and develop novel drugs used as standalone therapies or to prevent tumor recurrence following treatment with a variety of approved anti-cancer therapies.

CU's TTO pursues, protects, packages and licenses to business the intellectual property generated from research at CU. The office provides assistance to faculty, staff and students, as well as to businesses looking to license or invest in CU technology.


'/>"/>

Contact: Lindsay Lennox
lindsay.lennox@cu.edu
303-735-5518
University of Colorado at Boulder
Source:Eurekalert

Related biology news :

1. CU-Boulder study suggests air quality regulations miss key pollutants
2. New CU-Boulder study shows diversity decreases chances of parasitic disease
3. Evolution education for K-12 teachers needs beefing up, says CU-Boulder professor
4. CU-Boulder study shows 53 million-year-old high Arctic mammals wintered in darkness
5. CU-Boulder study shows Maya intensively cultivated manioc 1,400 years ago
6. Noise pollution negatively affects woodland bird communities, says CU-Boulder study
7. Daily bathroom showers may deliver face full of pathogens, says CU-Boulder study
8. CU-Boulder team identifies DNA "barcodes to help track illegal trading of wildlife products
9. 3 payloads built by CU-Boulder set for launch on space shuttle Atlantis
10. Swan song of space shuttle Discovery to carry 2 payloads built by CU-Boulder
11. Final flight of space shuttle Discovery to carry 2 payloads built by CU-Boulder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , ... March 21, 2017 , ... ... , more than tripling its goal and raising over $30,000 in the first ... that grows nutritious veggies & herbs fast, easy, and affordably, anywhere. , “Simply ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered by the ... feed pumps in SU tangential flow filtration (TFF), virus filtration (VF) and ...
(Date:3/22/2017)... , ... March 22, 2017 , ... The Society for ... agencies as outlined in the Administration’s recently published fiscal year 2018 budget request. ... Institutes of Health (NIH) by $5.8 billion or roughly 20% of its total budget. ...
(Date:3/22/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... Lebovits , Chief Executive Officer, will provide an update ... Associates 2 nd Annual Neuroscience Biopartnering and Investment ... the New York Academy of Sciences. ...
Breaking Biology Technology: